美国糖尿病人群他汀治疗后残余高甘油三酯血症与ASCVD风险
他汀使用者中二者患病率分别为20.0%和19.5%,即使LDL-C<70 mg/dL者仍达16.8%和16.7%;约77.5%的高甘油三酯血症者10年ASCVD风险≥7.5%。
要点
- 他汀治疗的糖尿病成人中残余高甘油三酯血症常见,LDL-C达标者亦不能幸免。
- 高甘油三酯血症的糖尿病成人约77.5%处于10年ASCVD风险≥7.5%。
- 需加强生活方式与药物干预以处理残余高甘油三酯血症。
核心结论
- 超过四分之三伴高甘油三酯血症的糖尿病成人10年ASCVD风险处于中等或高水平。
研究设计与样本
- 按他汀使用与LDL-C水平比较边缘性高甘油三酯血症(TG 150-199 mg/dL)和高甘油三酯血症(TG≥200 mg/dL)患病率。
- 用logistic回归识别高甘油三酯血症的危险因素,并估算无既往ASCVD者的10年ASCVD风险。
主要发现
- 他汀使用者中边缘性高甘油三酯血症与高甘油三酯血症患病率分别为20.0%和19.5%,非他汀使用者分别为20.1%和25.3%(P < 0.0001)。
- 他汀使用者中LDL-C <70 mg/dL者边缘性高甘油三酯血症患病率为16.8%,高甘油三酯血症为16.7%。
- 高甘油三酯血症者中约77.5%的10年ASCVD风险≥7.5%,他汀使用者中近40%的ASCVD风险≥20%。
关键数值与推荐
- 边缘性高甘油三酯血症定义为TG 150-199 mg/dL,高甘油三酯血症定义为TG≥200 mg/dL。
- 他汀使用者与非使用者高甘油三酯血症患病率比较的P < 0.0001。
- 10年ASCVD风险分层界值包括≥7.5%与≥20%。
临床怎么用
- 对糖尿病患者在他汀治疗、LDL-C达标后仍应关注甘油三酯水平,评估残余ASCVD风险。
- 对伴高甘油三酯血症者应强化生活方式及药物治疗以降低残余风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hypertriglyceridemia (HTG) is common in patients with diabetes, and statins remain the first-line therapy. However, the proportion of patients with diabetes having elevated triglycerides (TGs) on statin treatment and their atherosclerotic cardiovascular disease (ASCVD) risk has not been described. We quantified the prevalence of HTG in U.S. adults with diabetes currently treated versus not treated with statins and the estimated 10-year ASCVD risk. RESEARCH DESIGN AND METHODS: Among 1,448 U.S. adults aged 20 years and over with diabetes (projected to 24.4 million) in the 2007-2014 National Health and Nutrition Examination Survey (NHANES), we compared the prevalence of borderline HTG (TG 150-199 mg/dL) and HTG (TG ≥200 mg/dL) by statin use and LDL cholesterol (LDL-C) levels, and we used logistic regression to identify risk factors for HTG. We also estimated the 10-year ASCVD risk in those without prior ASCVD. RESULTS: The prevalence of borderline HTG and HTG was 20.0% and 19.5%, respectively, in statin users and 20.1% and 25.3%, respectively, in nonstatin users (P < 0.0001). Even among statin users with LDL-C <70 mg/dL, borderline HTG prevalence was 16.8% and HTG prevalence was 16.7%. Approximately 77.5% of those with HTG had an estimated 10-year ASCVD risk of ≥7.5%, with almost 40% of statin users having ASCVD risk ≥20%. CONCLUSIONS: Residual HTG occurs in over one-fifth (∼5.5 million) of U.S. adults with diabetes, including those on statin therapy and with well-controlled LDL-C. Over three-quarters of adults with diabetes with HTG are at moderate or high 10-year risk for ASCVD. Greater efforts are needed to promote lifestyle and pharmacologic means to address residual HTG.
引用
- Fan W, Philip S, Granowitz C, et al. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014. Diabetes Care. 2019. PMID: 31575639. doi:10.2337/dc19-0501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。